Implementing non-invasive markers for liver fibrosis in clinical practice.
Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.
Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C.
Diagnostic algorithms for liver fibrosis in hepatitis C: are they ready to avoid liver biopsy?
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.
Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases.
Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.
Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.
Toward non-invasive assessment strategies in autoimmune hepatitis.
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.
